COMP <GO>
SRTA vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Strata Critical Medical Inc. (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SRTA 2
— JNJ 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $4.44 (-6.53%) • MKT CAP: $420.2M
balance-sheet
5.58
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRTA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRTA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.90% | 67.90% | -47.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.10% | 25.50% | -32.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.92% | 2.97% | -16.89 | JNJ | /fcf-yield <GO> |
| Operating Margin | -11.30% | 34.70% | -46.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 28.50% | -7.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 34.30% | 6.00% | +28.30 | SRTA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.58 | 5.59 | -0.01 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 62.1 | -13.00 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 23.0x | -14.40 | SRTA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $420.2M | $662.49B | -$662.07B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRTA REV | JNJ REV | SRTA GROSS % | JNJ GROSS % | SRTA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $197.1M | $94.19B | 20.9% | 67.9% | -$58.5M | $19.70B |
| FY 2024 | $146.8M | $88.82B | 20.2% | 69.1% | -$33.4M | $19.84B |
| FY 2023 | $225.2M | $85.16B | — | — | -$32.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRTA // BETA —
JNJ // BETA 1.08